Construction and evaluation of novel rhesus monkey adenovirus vaccine vectors

Journal of Virology

Volumn 89, Issue 3, 2015, Pages 1512-1522

  Abbink, Peter ^a   Maxfield, Lori F ^a   Ng'ang'a, David ^a   Borducchi, Erica N ^a   Iampietro, M Justin ^a   Bricault, Christine A ^a   Teigler, Jeffrey E ^a   Blackmore, Stephen ^a   Parenteau, Lily ^a   Wagh, Kshitij ^c   Handley, Scott A ^d   Zhao, Guoyan ^d   Virgin, Herbert W ^d   Korber, Bette ^c   Barouch, Dan H ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c LOS ALAMOS NATIONAL LABORATORY   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VACCINE; CYTOKINE; VIRUS VECTOR; DRUG CARRIER; RECOMBINANT VACCINE; VIRUS ANTIBODY; VIRUS DNA;

ADAPTIVE IMMUNITY; ADENOVIRIDAE; ANIMAL EXPERIMENT; ARTICLE; CHIMPANZEE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; INNATE IMMUNITY; METAGENOMICS; MOLECULAR PHYLOGENY; MOUSE; NONHUMAN; RHESUS MONKEY; SEQUENCE ANALYSIS; SEROPREVALENCE; SPECIES DIFFERENCE; VIRUS IDENTIFICATION; VIRUS ISOLATION; ADENOVIRUS INFECTION; AFRICA SOUTH OF THE SAHARA; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CHEMISTRY; CLASSIFICATION; CLUSTER ANALYSIS; DNA SEQUENCE; EPIDEMIOLOGY; GENE VECTOR; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; MOLECULAR GENETICS; PHYLOGENY; VETERINARY; VIROLOGY;

ADENOVIRIDAE; CHIMPANZEE ADENOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA MULATTA; MUS;

ADENOVIRIDAE; ADENOVIRIDAE INFECTIONS; AFRICA SOUTH OF THE SAHARA; ANIMALS; ANTIBODIES, VIRAL; CLUSTER ANALYSIS; DNA, VIRAL; DRUG CARRIERS; GENETIC VECTORS; HUMANS; MACACA MULATTA; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PHYLOGENY; SEQUENCE ANALYSIS, DNA; SEROEPIDEMIOLOGIC STUDIES; VACCINES, SYNTHETIC;

EID: 84921506626     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02950-14     Document Type: Article

References (48)

1. Baden LR, Walsh SR, Seaman MS, Tucker RP, Krause KH, Patel A, Johnson JA, Kleinjan J, Yanosick KE, Perry J, Zablowsky E, Abbink P, Peter L, Iampietro MJ, Cheung A, Pau MG, Weijtens M, Goudsmit J, Swann E, Wolff M, Loblein H, Dolin R, Barouch DH. 2013. First-inhuman evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001). J Infect Dis 207:240-247. http://dx.doi.org/10.1093/infdis/jis670.
2. Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, Iampietro MJ, SanMiguel A, Seaman MS, Ferrari G, Forthal DN, Ourmanov I, Hirsch VM, Carville A, Mansfield KG, Stablein D, Pau MG, Schuitemaker H, Sadoff JC, Billings EA, Rao M, Robb ML, Kim JH, Marovich MA, Goudsmit J, Michael NL. 2012. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482:89-93. http://dx.doi.org/10.1038/nature10766.
3. Barouch DH, Stephenson KE, Borducchi EN, Smith K, Stanley K, McNally AG, Liu J, Abbink P, Maxfield LF, Seaman MS, Dugast AS, Alter G, Ferguson M, Li W, Earl PL, Moss B, Giorgi EE, Szinger JJ, Eller LA, Billings EA, Rao M, Tovanabutra S, Sanders-Buell E, Weijtens M, Pau MG, Schuitemaker H, Robb ML, Kim J H, Korber BT, Michael NL. 2013. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell 155:531-539. http://dx.doi.org/10.1016/j.cell.2013.09.061.
4. Hosseini SY, Sabahi F, Moazzeni SM, Modarressi MH, Saberi Firoozi M, Ravanshad M. 2012. Construction and preparation of three recombinant adenoviruses expressing truncated NS3 and core genes of hepatitis C virus for vaccine purposes. Hepat Mon 12:e6130. http://dx.doi.org/10.5812/hepatmon.6130.
5. Roshorm Y, Cottingham MG, Potash MJ, Volsky DJ, Hanke T. 2012. T cells induced by recombinant chimpanzee adenovirus alone and in primeboost regimens decrease chimeric EcoHIV/NDK challenge virus load. Eur J Immunol 42:3243-3255. http://dx.doi.org/10.1002/eji.201242624.
6. Smaill F, Jeyanathan M, Smieja M, Medina MF, Thanthrige-Don N, Zganiacz A, Yin C, Heriazon A, Damjanovic D, Puri L, Hamid J, Xie F, Foley R, Bramson J, Gauldie J, Xing Z. 2013. A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity. Sci Transl Med 5:205ra134. http://dx.doi.org/10.1126/scitranslmed.3006843.
7. Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, Smits S, Holterman L, Damen I, Vogels R, Thorner AR, O'Brien KL, Carville A, Mansfield KG, Goudsmit J, Havenga MJ, Barouch DH. 2007. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 81:4654-4663. http://dx.doi.org/10.1128/JVI.02696-06.
8. Belousova N, Mikheeva G, Xiong C, Soghomonian S, Young D, Le Roux L, Naff K, Bidaut L, Wei W, Li C, Gelovani J, Krasnykh V. 2010. Development of a targeted gene vector platform based on simian adenovirus serotype 24. J Virol 84:10087-10101. http://dx.doi.org/10.1128/JVI.02425-09.
9. Capone S, D'Alise AM, Ammendola V, Colloca S, Cortese R, Nicosia A, Folgori A. 2013. Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials. Expert Rev Vaccines 12:379-393. http://dx.doi.org/10.1586/erv.13.15.
10. Chen H, Xiang ZQ, Li Y, Kurupati RK, Jia B, Bian A, Zhou DM, Hutnick N, Yuan S, Gray C, Serwanga J, Auma B, Kaleebu P, Zhou X, Betts MR, Ertl HC. 2010. Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae. J Virol 84:10522-10532. http://dx.doi.org/10.1128/JVI.00450-10.
11. Colloca S, Barnes E, Folgori A, Ammendola V, Capone S, Cirillo A, Siani L, Naddeo M, Grazioli F, Esposito ML, Ambrosio M, Sparacino A, Bartiromo M, Meola A, Smith K, Kurioka A, O'Hara GA, Ewer KJ, Anagnostou N, Bliss C, Hill AV, Traboni C, Klenerman P, Cortese R, Nicosia A. 2012. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med 4:115ra112. http://dx.doi.org/10.1126/scitranslmed.3002925.
12. Dicks MD, Spencer AJ, Edwards NJ, Wadell G, Bojang K, Gilbert SC, Hill AV, Cottingham MG. 2012. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS One 7:e40385. http://dx.doi.org/10.1371/journal.pone.0040385.
13. O'Hara GA, Duncan CJ, Ewer KJ, Collins KA, Elias SC, Halstead FD, Goodman AL, Edwards NJ, Reyes-Sandoval A, Bird P, Rowland R, Sheehy SH, Poulton ID, Hutchings C, Todryk S, Andrews L, Folgori A, Berrie E, Moyle S, Nicosia A, Colloca S, Cortese R, Siani L, Lawrie AM, Gilbert SC, Hill AV. 2012. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis 205:772-781. http://dx.doi.org/10.1093/infdis/jir850.
14. Roy S, Medina-Jaszek A, Wilson MJ, Sandhu A, Calcedo R, Lin J, Wilson JM. 2011. Creation of a panel of vectors based on ape adenovirus isolates. J Gene Med 13:17-25. http://dx.doi.org/10.1002/jgm.1530.
15. Tatsis N, Tesema L, Robinson ER, Giles-Davis W, McCoy K, Gao GP, Wilson J M, Ertl HC. 2006. Chimpanzee-origin adenovirus vectors as vaccine carriers. Gene Ther 13:421-429. http://dx.doi.org/10.1038/sj.gt.3302675.
16. Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, de Bethune MP, Kostense S, Penders G, Helmus N, Koudstaal W, Cecchini M, Wetterwald A, Sprangers M, Lemckert A, Ophorst O, Koel B, van Meerendonk M, Quax P, Panitti L, Grimbergen J, Bout A, Goudsmit J, Havenga M. 2003. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 77:8263-8271. http://dx.doi.org/10.1128/JVI.77.15.8263-8271.2003.
17. Reddy PS, Idamakanti N, Chen Y, Whale T, Babiuk LA, Mehtali M, Tikoo SK. 1999. Replication-defective bovine adenovirus type 3 as an expression vector. J Virol 73:9137-9144.
18. Tutykhina IL, Shmarov MM, Logunov D, Grabko VI, Sevast'ianova GA, Naroditskii BS, Gintsburg AL. 2008. Construction of the vector based on the CELO avian adenovirus genome providing enhanced expression of secreted alkaline phosphatase gene in a non-permissive system in vitro and in vivo. Mol Gen Mikrobiol Virusol 2008:26-30. (In Russian.) http://dx.doi.org/10.3103/S089141680804006X.
19. Barouch DH, Kik SV, Weverling GJ, Dilan R, King SL, Maxfield LF, Clark S, Ng'ang'a D, Brandariz KL, Abbink P, Sinangil F, de Bruyn G, Gray GE, Roux S, Bekker LG, Dilraj A, Kibuuka H, Robb ML, Michael NL, Anzala O, Amornkul PN, Gilmour J, Hural J, Buchbinder SP, Seaman MS, Dolin R, Baden LR, Carville A, Mansfield KG, Pau MG, Goudsmit J. 2011. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine 29:5203-5209. http://dx.doi.org/10.1016/j.vaccine.2011.05.025.
20. + T cell activation in rhesus macaques following vaccination with an adenoviral vector. J Virol 88:8468-8478. http://dx.doi.org/10.1128/JVI.03850-13.
21. Ersching J, Hernandez MI, Cezarotto FS, Ferreira JD, Martins AB, Switzer WM, Xiang Z, Ertl HC, Zanetti CR, Pinto AR. 2010. Neutralizing antibodies to human and simian adenoviruses in humans and New-World monkeys. Virology 407:1-6. http://dx.doi.org/10.1016/j.virol.2010.07.043.
22. Jian L, Zhao Q, Zhang S, Huang W, Xiong Y, Zhou X, Jia B. 2014. The prevalence of neutralising antibodies to chimpanzee adenovirus type 6 and type 7 in healthy adult volunteers, patients with chronic hepatitis B and patients with primary hepatocellular carcinoma in China. Arch Virol 159:465-470. http://dx.doi.org/10.1007/s00705-013-1828-y.
23. + T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization. J Immunol 190:2720-2735. http://dx.doi.org/10.4049/jimmunol.1202861.
24. Roy S, Vandenberghe LH, Kryazhimskiy S, Grant R, Calcedo R, Yuan X, Keough M, Sandhu A, Wang Q, Medina-Jaszek CA, Plotkin JB, Wilson JM. 2009. Isolation and characterization of adenoviruses persistently shed from the gastrointestinal tract of non-human primates. PLoS Pathog 5:e1000503. http://dx.doi.org/10.1371/journal.ppat.1000503.
25. Handley SA, Thackray LB, Zhao G, Presti R, Miller AD, Droit L, Abbink P, Maxfield LF, Kambal A, Duan E, Stanley K, Kramer J, Macri SC, Permar SR, Schmitz JE, Mansfield K, Brenchley JM, Veazey RS, Stappenbeck TS, Wang D, Barouch DH, Virgin HW. 2012. Pathogenic simian immunodeficiency virus infection is associated with expansion of the enteric virome. Cell 151:253-266. http://dx.doi.org/10.1016/j.cell.2012.09.024.
26. Lemckert AA, Grimbergen J, Smits S, Hartkoorn E, Holterman L, Berkhout B, Barouch DH, Vogels R, Quax P, Goudsmit J, Havenga MJ. 2006. Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity. J Gen Virol 87:2891-2899. http://dx.doi.org/10.1099/vir.0.82079-0.
27. Price MN, Dehal PS, Arkin AP. 2010. FastTree 2-approximately maximum-likelihood trees for large alignments. PLoS One 5:e9490. http://dx.doi.org/10.1371/journal.pone.0009490.
28. Katoh K, Standley DM. 2013. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol Biol Evol 30:772-780. http://dx.doi.org/10.1093/molbev/mst010.
29. Siepel AC, Halpern AL, Macken C, Korber BT. 1995. A computer program designed to screen rapidly for HIV type 1 intersubtype recombinant sequences. AIDS Res Hum Retroviruses 11:1413-1416. http://dx.doi.org/10.1089/aid.1995.11.1413.
30. Sprangers MC, Lakhai W, Koudstaal W, Verhoeven M, Koel BF, Vogels R, Goudsmit J, Havenga MJ, Kostense S. 2003. Quantifying adenovirusneutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol 41:5046-5052. http://dx.doi.org/10.1128/JCM.41.11.5046-5052.2003.
31. Barouch DH, Pau MG, Custers JH, Koudstaal W, Kostense S, Havenga MJ, Truitt DM, Sumida SM, Kishko MG, Arthur JC, Korioth-Schmitz B, Newberg MH, Gorgone DA, Lifton MA, Panicali DL, Nabel GJ, Letvin NL, Goudsmit J. 2004. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 172:6290-6297. http://dx.doi.org/10.4049/jimmunol.172.10.6290.
32. + T-lymphocyte epitope immunodominance hierarchies. J Virol 80:11991-11997. http://dx.doi.org/10.1128/JVI.01348-06.
33. Teigler JE, Iampietro MJ, Barouch DH. 2012. Vaccination with adenovirus serotypes 35, 26, and 48 elicits higher levels of innate cytokine responses than adenovirus serotype 5 in rhesus monkeys. J Virol 86:9590-9598. http://dx.doi.org/10.1128/JVI.00740-12.
34. Teigler JE, Phogat S, Franchini G, Hirsch VM, Michael NL, Barouch DH. 2014. The canarypox virus vector ALVAC induces distinct cytokine responses compared to the vaccinia virus-based vectors MVA and NYVAC in rhesus monkeys. J Virol 88:1809-1814. http://dx.doi.org/10.1128/JVI.02386-13.
35. Barouch DH, Liu J, Peter L, Abbink P, Iampietro MJ, Cheung A, Alter G, Chung A, Dugast AS, Frahm N, McElrath MJ, Wenschuh H, Reimer U, Seaman MS, Pau MG, Weijtens M, Goudsmit J, Walsh SR, Dolin R, Baden LR. 2013. Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001). J Infect Dis 207:248-256. http://dx.doi.org/10.1093/infdis/jis671.
36. Dehghan S, Seto J, Liu EB, Walsh MP, Dyer DW, Chodosh J, Seto D. 2013. Computational analysis of four human adenovirus type 4 genomes reveals molecular evolution through two interspecies recombination events. Virology 443:197-207. http://dx.doi.org/10.1016/j.virol.2013.05.014.
37. Fujimoto T, Yamane S, Ogawa T, Hanaoka N, Ogura A, Hotta C, Niwa T, Chiba Y, Gonzalez G, Aoki K, Koyanagi KO, Watanabe H. 2014. A novel complex recombinant form of type 48-related human adenovirus species D isolated in Japan. Jpn J Infect Dis 67:282-287. http://dx.doi.org/10.7883/yoken.67.282.
38. Gonzalez G, Koyanagi KO, Aoki K, Kitaichi N, Ohno S, Kaneko H, Ishida S, Watanabe H. 2014. Intertypic modular exchanges of genomic segments by homologous recombination at universally conserved segments in human adenovirus species D. Gene 547:10-17. http://dx.doi.org/10.1016/j.gene.2014.04.018.
39. Robinson CM, Singh G, Lee JY, Dehghan S, Rajaiya J, Liu EB, Yousuf MA, Betensky RA, Jones MS, Dyer DW, Seto D, Chodosh J. 2013. Molecular evolution of human adenoviruses. Sci Rep 3:1812. http://dx.doi.org/10.1038/srep01812.
40. Mast TC, Kierstead L, Gupta SB, Nikas AA, Kallas EG, Novitsky V, Mbewe B, Pitisuttithum P, Schechter M, Vardas E, Wolfe ND, Aste-Amezaga M, Casimiro DR, Coplan P, Straus WL, Shiver JW. 2010. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 28:950-957. http://dx.doi.org/10.1016/j.vaccine.2009.10.145.
41. Li H, Rhee EG, Masek-Hammerman K, Teigler JE, Abbink P, Barouch DH. 2012. Adenovirus serotype 26 utilizes CD46 as a primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys. J Virol 86:10862-10865. http://dx.doi.org/10.1128/JVI.00928-12.
42. Zhang Y, Bergelson JM. 2005. Adenovirus receptors. J Virol 79:12125-12131. http://dx.doi.org/10.1128/JVI.79.19.12125-12131.2005.
43. Baden LR, Liu J, Li H, Johnson JA, Walsh SR, Kleinjan JA, Engelson BA, Peter L, Abbink P, Milner DA, Jr, Golden KL, Viani KL, Stachler MD, Chen BJ, Pau MG, Weijten M, Carey BR, Miller CA, Swann EM, Wolff M, Loblein H, Seaman MS, Dolin R, Barouch DH. 26 August 2014. Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans. J Infect Dis. http://dx.doi.org/10.1093/infdis/jiu485.
44. Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A, Meyer J, Huddart R, Smith K, Townsend R, Brown A, Antrobus R, Ammendola V, Naddeo M, O'Hara G, Willberg C, Harrison A, Grazioli F, Esposito ML, Siani L, Traboni C, Oo Y, Adams D, Hill A, Colloca S, Nicosia A, Cortese R, Klenerman P. 2012. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 4:115ra111. http://dx.doi.org/10.1126/scitranslmed.3003155.
45. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, McElrath MJ, Casimiro DR, Gottesdiener KM, Chodakewitz JA, Corey L, Robertson MN. 2008. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372:1881-1893. http://dx.doi.org/10.1016/S0140-6736(08)61591-3.
46. Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, Koblin BA, Buchbinder SP, Keefer MC, Tomaras GD, Frahm N, Hural J, Anude C, Graham BS, Enama ME, Adams E, DeJesus E, Novak RM, Frank I, Bentley C, Ramirez S, Fu R, Koup RA, Mascola JR, Nabel GJ, Montefiori DC, Kublin J, McElrath MJ, Corey L, Gilbert PB. 2013. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med 369:2083-2092. http://dx.doi.org/10.1056/NEJMoa1310566.
47. Xiang ZQ, Greenberg L, Ertl HC, Rupprecht CE. 2014. Protection of non-human primates against rabies with an adenovirus recombinant vaccine. Virology 450-451:243-249. http://dx.doi.org/10.1016/j.virol.2013.12.029.
48. Vitelli A, Quirion MR, Lo CY, Misplon JA, Grabowska AK, Pierantoni A, Ammendola V, Price GE, Soboleski MR, Cortese R, Colloca S, Nicosia A, Epstein SL. 2013. Vaccination to conserved influenza antigens in mice using a novel simian adenovirus vector, PanAd3, derived from the bonobo Pan paniscus. PLoS One 8:e55435. http://dx.doi.org/10.1371/journal.pone.0055435.